Table 3.
Baseline characteristics of the participants with hypertension (without diabetes) who were tested for ACR at baseline
| Cohort (country) | N | Age, mean (SD), years | Women, No. (%) | SBP, mean (SD), mmHg | Any HTN med use, No. (%) | RAAS inhibitor use, No. (%) | Other HTN med use, No. (%) | No. (%) of participants | BMI, mean (SD), Kg/m2 | eGFR, mean (SD), ml/min/ 1.73 m2 | ACR ≥30 mg/g, No. (%) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| History of CHD | History of HF | |||||||||||
| Development : research cohorts | ||||||||||||
| Pima (US) | 205 | 33 (15) | 43 (21) | 141 (15) | 55 (27) | 24 (18) | 31 (15) | NA | 0 (0) | 36 (7) | 119 (17) | 31 (15) |
| PREVEND (Netherlands) | 1917 | 61 (11) | 844 (44) | 143 (19) | 1095 (62) | 434 (23) | 661 (37) | 238 (12) | 43 (2) | 28 (4) | 86 (17) | 352 (18) |
| Rancho Bernardo (US) | 799 | 74 (10) | 485 (61) | 146 (20) | 518 (65) | NA | 518 (65) | 78 (10) | 28 (4) | 25 (4) | 63 (15) | 120 (15) |
| Development : clinical cohorts | ||||||||||||
| Geisinger (US) | 5299 | 68 (15) | 2938 (55) | 130 (17) | 4510 (85) | 2884 (54) | 3532 (67) | 1287 (24) | 397 (7) | 31 (7) | 66 (23) | 1101 (21) |
| Maccabi (Israel) | 18539 | 64 (13) | 8410 (45) | 137 (18) | 14134 (76) | 10494 (57) | 10114 (55) | 2713 (15) | 409 (2) | 30 (6) | 80 (22) | 7606 (41) |
| Mt Sinai BioMe (US) | 528 | 60 (13) | 317 (60) | 137 (22) | 322 (61) | 206 (39) | 278 (53) | 24 (5) | 63 (12) | 32 (9) | 71 (27) | 172 (33) |
| OLDW cohort 1 (US) | 858 | 66 (13) | 503 (59) | 131 (18) | 558 (65) | 252 (29) | 501 (58) | 184 (21) | 78 (9) | 32 (7) | 70 (22) | 185 (22) |
| OLDW cohort 2 (US) | 2684 | 62 (13) | 1576 (59) | 131 (18) | 1914 (71) | 1181 (44) | 1680 (63) | 491 (18) | 142 (5) | 32 (7) | 75 (24) | 579 (22) |
| OLDW cohort 4 (US) | 1490 | 63 (14) | 751 (50) | 150 (38) | 757 (51) | 313 (21) | 660 (44) | 285 (19) | 97 (7) | 31 (8) | 63 (26) | 563 (38) |
| OLDW cohort 6 (US) | 2200 | 61 (13) | 1231 (56) | 133 (18) | 712 (32) | 347 (16) | 616 (28) | 360 (16) | 112 (5) | 32 (7) | 76 (23) | 392 (18) |
| OLDW cohort 7 (US) | 1224 | 61 (14) | 587 (48) | 133 (18) | 558 (46) | 344 (28) | 436 (36) | 155 (13) | 35 (3) | 32 (7) | 78 (22) | 277 (23) |
| OLDW cohort 8 (US) | 2749 | 56 (13) | 1500 (55) | 141 (21) | 1521 (55) | 548 (20) | 1408 (51) | 382 (14) | 96 (3) | 34 (9) | 82 (23) | 613 (22) |
| OLDW cohort 9 (US) | 5910 | 60 (13) | 2544 (43) | 133 (18) | 3985 (67) | 2209 (37) | 3405 (58) | 952 (16) | 226 (4) | 31 (7) | 77 (23) | 1301 (22) |
| OLDW cohort 10 (US) | 2143 | 62 (13) | 1114 (52) | 134 (19) | 1489 (70) | 962 (45) | 1221 (57) | 346 (16) | 107 (5) | 32 (8) | 77 (22) | 416 (19) |
| OLDW cohort 11 (US) | 556 | 66 (13) | 342 (62) | 131 (19) | 330 (59) | 163 (29) | 281 (51) | 126 (23) | 60 (11) | 31 (7) | 64 (23) | 240 (43) |
| OLDW cohort 13 (US) | 2239 | 63 (13) | 1136 (51) | 130 (17) | 1198 (54) | 649 (29) | 986 (44) | 300 (13) | 69 (3) | 29 (6) | 78 (20) | 351 (16) |
| SCREAM (Sweden) | 3803 | 65 (15) | 1691 (44) | NA | 3339 (88) | 2208 (58) | 2871 (75) | 529 (14) | 454 (12) | NA | 68 (27) | 1650 (43) |
| West of Scotland (Scotland) | 1499 | 71 (13) | 814 (54) | 145 (25) | 705 (47) | 433 (29) | 546 (36) | 226 (15) | 72 (5) | 29 (8) | 38 (18) | 426 (28) |
| Total | 54642 | 63 (14) | 26826 (49) | 135 (19) | 37700 (69) | 23651 (44) | 29745 (55) | 8676 (16) | 2488 (5) | 31 (7) | 75 (24) | 16375 (30) |
| Validation : research cohorts | ||||||||||||
| UK Biobank (UK) | 213269 | 59 (7) | 105697 (50) | 153 (15) | 57138 (27) | 36818 (17) | 20320 (10) | 6243 (3) | 128 (0) | 28 (5) | 89 (13) | 12003 (6) |
| Validation : clinical cohorts | ||||||||||||
| CURE-CKD (US) | 2204 | 63 (15) | 1107 (50) | 132 (19) | NA | NA | NA | 215 (10) | 61 (3) | 29 (6) | 70 (26) | 595 (27) |
| OLDW cohort 14 (US) | 957 | 67 (12) | 460 (48) | 133 (18) | 674 (70) | 415 (43) | 566 (59) | 202 (21) | 48 (5) | 31 (7) | 68 (21) | 134 (14) |
| OLDW cohort 15 (US) | 740 | 58 (14) | 370 (50) | 136 (19) | 457 (62) | 284 (38) | 383 (52) | 87 (12) | 23 (3) | 32 (7) | 83 (24) | 193 (26) |
| OLDW cohort 17 (US) | 6497 | 64 (13) | 3482 (54) | 134 (18) | 4483 (69) | 2459 (38) | 3802 (59) | 1222 (19) | 316 (5) | 31 (7) | 74 (21) | 1417 (22) |
| OLDW cohort 18 (US) | 1433 | 64 (14) | 770 (54) | 132 (16) | 975 (68) | 499 (35) | 795 (55) | 289 (20) | 97 (7) | 31 (7) | 73 (22) | 322 (22) |
| RCAV (US) | 21445 | 66 (12) | 657 (3) | 134 (17) | 14785 (69) | 7719 (36) | 12190 (57) | 6431 (30) | 1606 (7) | 30 (6) | 77 (16) | 4078 (19) |
| Total | 246545 | 60 (9) | 112543 (46) | 151 (17) | 78583 (32) | 48202 (20) | 38127 (15) | 14689 (6) | 2279 (1) | 28 (5) | 87 (15) | 18742 (7) |
ACR, urine albumin-to-creatinine ratio; SD, standard deviation; SBP, systolic blood pressure; RAAS, renin-angiotensin-aldosterone system; HTN, hypertension; CHD, coronary heart disease; HF, heart failure; eGFR, estimated glomerular filtration rate; IQI, interquartile interval; BMI, body mass index; NA, not available; med, medication